A Phase 1B/2 Pan-Tumor, Open-Label Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is testing a new cancer treatment called ifinatamab deruxtecan (I-DXd). It works by using a specialized antibody to find cancer cells and then delivering a chemotherapy drug directly to them to help shrink tumors.
This trial is for adults (18+) with various types of solid tumors that have come back or spread after previous treatments. You must be active enough to perform daily activities and have tumor tissue available for study testing.
Participants will receive the study drug and be closely monitored by a medical team to see how well the treatment works and to track any side effects. You will have regular check-ups, including scans to measure your tumor's response to the therapy.
This study is currently recruiting patients at medical centers in Los Angeles and Whittier, California. You should talk to your oncologist to see if this trial might be a good fit for your specific health situation.
- 1The study tests a targeted therapy that delivers chemotherapy directly to cancer cells.
- 2It is open to many different types of solid cancers that have progressed after standard treatment.
- 3Participants receive close clinical supervision and regular monitoring to ensure safety and track progress.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.